We are live on ! Find out more
IMRX icon

Immuneering
IMRX

68 hedge funds and large institutions have $182M invested in Immuneering in 2025 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 23 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,312% more capital invested

Capital invested by funds: $12.9M → $182M (+$169M)

725% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 4

229% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 7

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

74% more funds holding

Funds holding: 39 → 68 (+29)

52% more ownership

Funds ownership: 10.64% → 62.65% (+52%)

Holders
68
Holders Change
+29
Holders Change %
+74.36%
% of All Funds
0.89%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
33
Increased
23
Reduced
7
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$44.5M
2
S
Sanofi
France
+$14.1M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$9.34M
4
ECM
ExodusPoint Capital Management
New York
+$7.87M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$7.05M

Top Sellers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
-$1.57M
2
Corient Private Wealth
Corient Private Wealth
Florida
-$143K
3
CSS
Cubist Systematic Strategies
Connecticut
-$99.1K
4
First Manhattan
First Manhattan
New York
-$41.9K
5
HighTower Advisors
HighTower Advisors
Illinois
-$18.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$61.5M +$44.5M +8,566,052 +3,876%
S
2
Sanofi
France
$19M +$14.1M +2,708,559 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$16.9M +$7.05M +1,358,322 +129%
T. Rowe Price Associates
4
T. Rowe Price Associates
Maryland
$12.6M +$9.34M +1,798,782 New
ECM
5
ExodusPoint Capital Management
New York
$10.6M +$7.87M +1,516,833 New
LGM
6
Logos Global Management
California
$6.65M +$4.93M +950,000 New
Citadel Advisors
7
Citadel Advisors
Florida
$6.6M +$4.89M +943,144 New
BlackRock
8
BlackRock
New York
$4.77M +$1.34M +258,427 +61%
BOCH
9
Blue Owl Capital Holdings
New York
$3.85M +$2.85M +550,000 New
Geode Capital Management
10
Geode Capital Management
Massachusetts
$3.6M +$1.47M +283,390 +123%
OCM
11
Occam Crest Management
Connecticut
$3.49M +$2.59M +498,498 New
BGM
12
Burkehill Global Management
New York
$2.1M +$1.56M +300,000 New
MIM
13
Monashee Investment Management
Massachusetts
$2.1M +$1.56M +300,000 New
Morgan Stanley
14
Morgan Stanley
New York
$2.06M +$487K +93,763 +47%
IAM
15
Iridian Asset Management
Connecticut
$1.93M +$1.43M +275,086 New
SM
16
Southport Management
Wyoming
$1.91M +$143K +27,501 +11%
Marshall Wace
17
Marshall Wace
United Kingdom
$1.9M -$1.57M -302,560 -53%
DC
18
Diametric Capital
Massachusetts
$1.77M +$1.31M +252,193 New
Millennium Management
19
Millennium Management
New York
$1.66M +$906K +174,532 +280%
State Street
20
State Street
Massachusetts
$1.21M +$392K +75,529 +78%
AIC
21
AWM Investment Company
New York
$1.05M +$778K +150,000 New
WP
22
Woodline Partners
California
$1.05M +$778K +150,000 New
TD Asset Management
23
TD Asset Management
Ontario, Canada
$1.02M +$753K +145,180 New
HighTower Advisors
24
HighTower Advisors
Illinois
$927K -$18.2K -3,501 -3%
UBS Group
25
UBS Group
Switzerland
$885K +$630K +121,329 +2,392%
1
2 3

IMRX Hedge Fund Activity: Q3 2025 in Review

68 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Immuneering (IMRX) for Q3 2025, worth a combined $182M — up 1,312% from $12.9M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new IMRX positions and 4 closed out — a net gain of 29 holders — while 23 added to existing stakes and 7 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $44.5M. The largest seller was Marshall Wace, cutting an estimated $1.57M.

  • 68 institutional investors held Immuneering (IMRX) as of Q3 2025, up from 39 in Q2 2025.
  • Funds reported $182M of Immuneering stock for Q3 2025, up 1,312% quarter-over-quarter.
  • 33 funds opened new Immuneering positions in Q3 2025 and 4 closed out, a net change of +29 holders.
  • The largest Immuneering buyer in Q3 2025 was Fidelity Investments, an estimated $44.5M added.
  • The largest Immuneering seller in Q3 2025 was Marshall Wace, an estimated $1.57M sold.

Based on aggregated 13F filings for Q3 2025.